417 related articles for article (PubMed ID: 12654763)
1. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
2. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
Low DE; Brown S; Felmingham D
Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
[TBL] [Abstract][Full Text] [Related]
3. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
Fogarty CM; Buchanan P; Aubier M; Baz M; van Rensburg D; Rangaraju M; Nusrat R
Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
[TBL] [Abstract][Full Text] [Related]
4. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin.
van Rensburg DJ; Fogarty C; Kohno S; Dunbar L; Rangaraju M; Nusrat R
Chemotherapy; 2005 Jul; 51(4):186-92. PubMed ID: 15980629
[TBL] [Abstract][Full Text] [Related]
6. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
8. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
9. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
[TBL] [Abstract][Full Text] [Related]
10. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
Carbon C
Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
[TBL] [Abstract][Full Text] [Related]
11. The ketolides: a critical review.
Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004).
Blasi F; Farrell DJ; Dubreuil L
Diagn Microbiol Infect Dis; 2009 Mar; 63(3):302-8. PubMed ID: 19135821
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
Reinert RR
J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000).
Felmingham D; Farrell DJ; Reinert RR; Morrissey I
J Infect; 2004 Jan; 48(1):39-55. PubMed ID: 14667791
[TBL] [Abstract][Full Text] [Related]
17. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
18. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
Low DE; Felmingham D; Brown SD; Rangaraju M; Nusrat R
J Infect; 2004 Aug; 49(2):115-25. PubMed ID: 15236918
[TBL] [Abstract][Full Text] [Related]
19. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
Jenkins SG; Brown SD; Farrell DJ
Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae.
van Rensburg D; Fogarty C; De Salvo MC; Rangaraju M; Nusrat R
J Infect; 2005 Oct; 51(3):201-5. PubMed ID: 16230216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
